Evercore ISI says that while neither OptumRx nor Cardinal Health (CAH) would confirm the winner of the contract, McKesson (MCK) confirmed it had won the contract beginning in July. Cardinal this morning announced that its pharmaceutical distribution contracts with OptumRx, which represented 16% of fiscal 2023 revenue, is expiring at end of June and will not be renewed. Evercore estimates the win would represent a 50c-65c earnings per share benefit to McKesson on a full-year basis or likely half of that given the contract does not start until July. The firm does not see Cardinal’s announcement as “heralding a broadly more competitive period for the distributors, but rather a one-off contract shift given what was likely an off-market contract.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- Early notable gainers among liquid option names on April 10th
- McKesson price target raised to $570 from $510 at Argus
- Notable companies reporting before tomorrow’s open
- McCormick stock about to shake things up, Barron’s says
- Rockwell Automation announces Stephen Ford as chief information security officer
